PeptiDream (4587) investor relations material

Executive summary

• Revenue for Q1 2026 was ¥4,764.9 million, up 12.6% year-over-year, driven by growth in both Radiopharmaceutical and Drug Discovery segments.

• Net loss attributable to owners was ¥854.9 million, an improvement of ¥178.5 million year-over-year.

• Core operating loss narrowed to ¥1,067.1 million, a ¥288.6 million improvement year-over-year.

• Radiopharmaceuticals business saw continued product launches and pipeline progress, while Drug Discovery advanced multiple clinical and preclinical programs.

Financial highlights

• Revenue increased by ¥531.7 million year-over-year to ¥4,764.9 million.

• Core operating loss improved to ¥1,067.1 million from ¥1,355.7 million year-over-year.

• Net loss attributable to owners improved to ¥854.9 million from ¥1,033.4 million year-over-year.

• Basic and diluted loss per share improved to ¥6.62 from ¥7.97 year-over-year.

• Cash and cash equivalents at quarter-end were ¥25,551 million, down ¥3,132 million from year-end 2025.

Outlook and guidance

• FY2026 revenue forecast is ¥32,000 million, up 72.8% year-over-year.

• Core operating profit forecasted at ¥4,600 million, with profit attributable to owners projected at ¥3,000 million.

• Forecast excludes potential out-licensing of key oral programs.